These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34298857)

  • 1. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
    Kelly D; Rose AAN; Muniz TP; Hogg D; Butler MO; Saibil SD; King I; Kamil ZS; Ghazarian D; Ross K; Iafolla M; Araujo DV; Waldron J; Laperriere N; Krema H; Spreafico A
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
    Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T
    Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma.
    Waninger JJ; Fecher LA; Lao C; Yentz S; Green MD; Demirci H
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study.
    Vanaken L; Woei-A-Jin FJSH; Van Ginderdeuren R; Deroose CM; Laenen A; Missotten G; Thal DR; Bechter O; Schöffski P; Clement P
    Acta Oncol; 2023 May; 62(5):480-487. PubMed ID: 37200223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland.
    Staeger R; Martínez-Gómez JM; Turko P; Ramelyte E; Kraehenbuehl L; Del Prete V; Hasan Ali O; Levesque MP; Dummer R; Nägeli MC; Mangana J
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473216
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    de Kouchkovsky I; Zhang L; Philip EJ; Wright F; Kim DM; Natesan D; Kwon D; Ho H; Ho S; Chan E; Porten SP; Wong AC; Desai A; Huang FW; Chou J; Oh DY; Pruthi RS; Fong L; Small EJ; Friedlander TW; Koshkin VS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups.
    Trommer M; Adams A; Celik E; Fan J; Funken D; Herter JM; Linde P; Morgenthaler J; Wegen S; Mauch C; Franklin C; Galldiks N; Werner JM; Kocher M; Rueß D; Ruge M; Meißner AK; Baues C; Marnitz S
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: a systematic review and individual patient data meta-analysis.
    Teo AYT; Yau CE; Low CE; Pereira JV; Ng JYX; Soong TK; Lo JYT; Yang VS
    EClinicalMedicine; 2024 Nov; 77():102870. PubMed ID: 39416390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study.
    Haist M; Stege H; Pemler S; Heinz J; Fleischer MI; Graf C; Ruf W; Loquai C; Grabbe S
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis.
    Pham JP; On L; Ardolino L; Hurwitz J; Salaun H; Sim HW; Joshua AM
    Melanoma Res; 2023 Aug; 33(4):316-325. PubMed ID: 37199712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors.
    Vlachostergios PJ
    Am J Transl Res; 2021; 13(11):12386-12394. PubMed ID: 34956460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
    Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM
    Melanoma Res; 2018 Dec; 28(6):571-577. PubMed ID: 30067547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical determinants of long-term survival in metastatic uveal melanoma.
    Koch EAT; Petzold A; Wessely A; Dippel E; Erdmann M; Heinzerling L; Hohberger B; Knorr H; Leiter U; Meier F; Mohr P; Rahimi F; Schell B; Schlaak M; Terheyden P; Schuler-Thurner B; Ugurel S; Utikal J; Vera J; Weichenthal M; Ziller F; Berking C; Heppt MV
    Cancer Immunol Immunother; 2022 Jun; 71(6):1467-1477. PubMed ID: 34709438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
    Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
    J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
    Blomen CL; Kött J; Hartung TI; Torster LK; Gebhardt C
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
    Lamba N; Ott PA; Iorgulescu JB
    JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.